潘扬;曹文锋;

• 1:南昌大学医学院
• 2:江西省人民医院神经内科

摘要(Abstract)：

<正>1流行病学地域分布上,最初认为烟雾病(moyamoya disease,MMD)仅发生在日本,但现已明确其在世界各地均有报道,主要发生在亚洲国家,以日本为著。发病年龄上,既往认为本病发病年龄呈双峰表现,分别是儿童期(4岁左右)和中年期(30⁴0岁),平均年龄29.25岁,儿童较为多见,儿童与成人的发病率之比为52;而现在认为,男性患者有3个发病高峰,分别是1040岁),平均年龄29.25岁,儿童较为多见,儿童与成人的发病率之比为52;而现在认为,男性患者有3个发病高峰,分别是10¹4岁、3514岁、35³9岁和5539岁和55⁵9岁,而女性有2

关键词(KeyWords)： 烟雾病;脑血管造影;抗血小板聚集;脑血管重建;遗传易感性

Abstract:

Keywords:

基金项目(Foundation): 江西省科技计划项目(20132BBG70064)

作者(Authors): 潘扬;曹文锋;

参考文献(References)：

• [1]Kim JS.Moyamoya disease:epidemicology,clinical features,and diagnosis[J].J Stroke,2016,18(Suppl 1):2-11.
• [2]Tanigawara T,Yamada H,Iwamura M.Studies on cytomegalovirus and Epstein-Barr virus infection in moyamoya disease[J].Clin Neurol Neuros,1997,99:225-228.
• [3]Charles K,Hammond FWACP,Shapson-Coe A,et al.Moyamoya Syndrome in South African Children With HIV-1Infection[J].J Child Neurol,2016,31(Suppl 8):1010-1 017.
• [4]Amano T,Inoha S,Wu CM,et al.Serum alpha 1-antitrypsin level and phenotype associated with familial moyamoya disease[J].Child Nerv Syst,2003,19(Suppl9):655-658.
• [5]Kang HS,Moon YJ,Kim YY,et al.Plasma matrix metalloproteinases,cytokines and angiogenic factors in moyamoya disease[J].J Neurol Neuros Ps,2010,81(Suppl6):673-678.
• [6]Soriano SG,Cowan DB,Proctor MR,et al.Levels of soluble adhesion molecules are elevated in the cerebrospinal fluid of children with moyamoya syndrome[J].J Neurosurg,2002,50(Suppl 3):544-549.
• [7]Yanagawa Y,Sugiura T,Suzuki K,et al.Moyamoya disease associated with positive findings for rheumatoid factor and myeloperoxidase-anti-neutrophil cytoplasmic antibody[J].W Indian Med J,2007,56(Suppl 3):282-284.
• [8]Bernard TJ,Fenton LZ,Apkon SD,et al.Biomarkers of hypercoagulability and inflammation in childhood-onset arterial ischemic stroke[J].Pediatrics,2010,156(Suppl4):651-656.
• [9]Ni G,Liu W,Huang X,et al.Increased levels of irculating SDF-1αand CD34+CXCR4+cells in patients with moyamoya disease[J].Eur J Neurol,2011,18(Suppl11):1 304-1 309.
• [10]Park YS.Single nucleotide polymorphism in patients with moyamoya disease[J].J Korean Neurosurg S,2015,57(Suppl 6):422-427.
• [11]Munot P,Saunders DE,Milewicz DM,et al.A novel distinctive cerebrovascular phenotype is associated with heterozygous Arg179 ACTA2 mutations[J].J Brain,2012,135(Suppl 8):2 506-2 514.
• [12]Kamada F,Aoki Y,Narisawa A,et al.A genome-wide association study identifies RNF213as the first moyamoya disease gene[J].Hum Genet,2011,56(Suppl1):34-40.
• [13]Liu W,Morito D,Takashima S,et al.Identification of RNF213as a susceptibility gene for moyamoya disease and its possible role in vascular development[J].PLOS One,2011,6(Suppl 7):22 542.
• [14]Miyatake S,Miyake N,Touho H,et al Homozygous c.14576G>A variant of RNF213predicts early-on-set and severe form of moyamoya disease[J].J Neurology,2012,78(Suppl 11):803-810.
• [15]Kim EH,Yum MS,Ra YS,et al.Important of RNF213polymorphism on clinical features and long term outcome in moyamoya disease[J].J Neurosurg,2016,124(Suppl 5):1 221-1 227.
• [16]Matsuda Y,Mineharu MD,Kimura MD,et al.RNF213p.R4810K variant and intracranial arterial stenosis or occlusion in relatives of patients with moyamoya disease[J].J Stroke Cerebrovasc,2017,26(Suppl 6):1163-1 392.
• [17]Park MG,Shin JH,Lee SW,et al.RNF213rs112735431polymorphism in intracranial artery steno-occlusive disease and moyamoya disease in Koreans[J].Neurol Sci,2017,377:1-236.
• [18]Park YS,Joon YJ,Kim HS,et al.The GC+CC genotype at position-418in TIMP-2 promoter and the-1575GA/-1306CC genotype in MMP-2is genetic predisposing factors for prevalence of moyamoya disease[J].BMC Neurol,2014,4(Suppl 14):180.
• [19]Kainth DS,Chaudhry SA,Kainth HS,et al.Prevalenceand characteristics of concurrent down syndrome in patients with moyamoya disease[J].J Neurosurg,2013,72(Suppl 2):210-215.
• [20]Hong SH,Wang KC,Kim SK,et al.Association of HLA-DR and-DQ genes with familial moyamoya disease in Koreans[J].J Korean Neurosurg S,2009,46(Suppl 6):558-563.
• [21]Smith ER,Scott RM.Spontaneous occlusion of the circle of Willis in children:pediatric moyamoya summary with proposed evidence-based practice guidelines.A review[J].J Neuros-Pediatr,2012,9(Suppl 4):353-360.
• [22]Kainth DS,Chaudhry SA,Kainth HS,et al.Prevalenceand characteristics of concurrent down syndrome in patients with moyamoya disease[J].J Neurosurg,2013,2(Suppl 72):210-215.
• [23]Ohba S,Nakagawa T,Murakami H.Consurrent Graves’disease and intracranial arteryial stenosis/occlusion:special considerations regarding the state of thyroid function,etiology and treatment[J].Neurosurg Rev,2011,34(Suppl 3):297-304.
• [24]Malik S,Andrew N.Angelos M,et al.Moyamoya syndrome associated with Graves’disease:a case report and review of the literature[J].J Stroke,2011,20(Suppl6):528-536.
• [25]Acker G,Goerdes S,Schneider UC,et al.Distinct clinical and radiographic characteristics of moyamoya disease amongst European Caucasians[J].Eur J Neurol,2015,22(Suppl 6):1 012-1 017.
• [26]Suzuki J,Kodama N.Moyamoya disease-a review[J].J Stroke,1983,14:104-109.
• [27]Kaku Y,Morioka M,Ohmori Y,et al.Outer-diameter narrowing of the internal carotid and middle cerebral arteries in moyamoya disease detected on 3D constractive interferrence in steady-state MR image:is arterial constravtive remodeling a major pathogenesis?[J].Acta Neurochir,2012,12(Suppl 154):2 151-2 157.
• [28]Yuan M,Liu ZQ,Wang ZQ,et al.High-resolution MR imaging of the arterial wall in moyamoya disease[J].Neurosci Lett,2015,584:77-82.
• [29]Zaheer F,Josepher R,Berger JR,et al.Moyamoya:another multiple sclerosis mimic[J].Mult Scler Relat Dis,2012,1(Suppl 2):100-103.
• [30]Dorfman LJ,Fischbein NJ,Woodard JI,et al.Moyamoya disease can masquerade as multiple sclerosis[J].Neurologist,2012,18(Suppl 6):398-403.
• [31]Preziosa P,Martinelli V,Ferre L,et al.Moyamoya disease mimicking the first attack of multiple sclerosis[J].J Neurol,2017,264(Suppl 5):1 005-1 007.
• [32]Kraemer M,Berlit P,Diesner F,et al.What is the experts option on antiplatelet therapy in moyamoya disease?Result of a worldwide survery[J].Eur J Neuro,2012,19(Suppl 1):163-167.
• [33]Yamada S,Oki K,Itoh Y,et al.Effects of surgery and antiplatelet therapy in ten-year follow-up from the registry study of moyamoya disease in Japan[J].J Stroke Cerebrovasc,2016,25(Suppl 2):340-349.
• [34]Kim T,Oh CW,Bang JS,et al.Moyamoya disease:treatment and outcomes[J].J Stroke,2016,18(Suppl1):21-30.
• [35]Sundanam S,Sylaya PN,Menon G,et al.Moyamoya disease:A comparison of long term outcome of conservative and surgical treatment in India[J].J Neuro Sci,2014,336:99-102.
• [36]Oyama H,Kito A,Maki H,et al.Cerebral hemorrhage and cerebral infarction in 30cases of adult moyamoya disease:comparison between conservative therapy and superficial temporal artery-middle cerebral artery anastomosis[J].Nagoya J Med Sci,2013,75:37.
• [37]Jiang HQ,Ni W,Xu B,et al.Outcome in adult patients with hemorrhagic moyamoya disease after combined extracranial-intracranial bypass clinical article[J].J Neurosurg,2014,121(Suppl 5):1 048-1 055.
• [38]Miyamoto S,Yoshimoto T,Hashimoto N,et al.Effects of extracranial-intracranial bypass for patients with hemorrhagic moyamoya disease:results of the Japan adult moyamoya trial[J].J Stroke,2014,45(Suppl 5):1415-1 421.
• [39]Kim DS,Huh PW,Kim HS,et al.Surgical treatment of moyamoya disease in adults:combined direct and indirectvs.Indirect bypass surgery[J].Neurol Med Chir,2012,52:333-338.
• [40]Choi IJ,Cho SJ,Chang JC,et al.Angiographic results ofindirect and combined bypass surgery for adult moyamoya disease[J].J Cerebrovasc Endovasc Neurosurg,2012,14(Suppl 3):216-222.
• [41]Zhang WG,Wang XR,Wang ZJ,et al.Effectiveness of superficial temporal artery-to-middle cerebral artery anastomosis in treating moyamoya disease by reducing endothelial progenitor cells[J].J World Neurosurg,2016,93:365-370.
• [42]Ge PC,Zhang Q,Ye X,et al.Long term outcome after conservative treatment and direct bypass surgery of moyamoya disease at late Suzuki stage[J].J World Neurosurg,2017,103:283-390.